Annexon Posts Q3 Loss of $0.25/Share, $213M Cash, Adds $200M Oxford Credit Facility
ANNX sits 67% above its 52-week low of $2.54.
Summary
Annexon reported a Q3 2026 net loss of $51.2M ($0.25 per share) with $213.4M in cash and investments funding operations into 2028, and added a credit facility of up to $200M with Oxford Finance, drawing $50M at closing. Both the tanruprubart BLA and the ARCHER II Month 15 DMC assessment are expected in Q4 2026.
Key Events · Earnings and Guidance · ANNX
-
Q3 Loss Narrows to $0.25/Share
Net loss attributable to common stockholders was $51.2M, or $0.25 per share, versus $54.9M, or $0.37 per share, in Q3 2025. R&D fell to $41.4M from $49.7M on lower contract manufacturing spend for tanruprubart filings.
-
$200M Oxford Credit Facility Signed
Annexon entered a strategic credit facility of up to $200M with Oxford Finance LLC and drew an initial $50M at closing. Another $100M is available on vonaprument and tanruprubart registrational milestones, with the remaining $50M subject to lender approval.
-
Cash Funds Operations Into 2028
Cash, cash equivalents and short-term investments totaled $213.4M as of September 30, 2026, which the company expects to fund operations and anticipated milestones into 2028.
-
Tanruprubart BLA Due Q4 2026
The U.S. BLA submission for tanruprubart in Guillain-Barré syndrome is anticipated in Q4 2026, strengthened by FORWARD data from 18 treated patients; the EU MAA is already under EMA review.
Analysis · ANNX · Life Sciences
Funding and timing are the heart of Annexon's Q3 update. The net loss narrowed to $51.2M ($0.25 per share) from $54.9M ($0.37 per share) a year ago, and $213.4M of cash plus short-term investments is expected to fund operations into 2028. What's new is a strategic credit facility of up to $200M with Oxford Finance, of which $50M was drawn at closing; another $100M unlocks on vonaprument and tanruprubart registrational milestones, and the last $50M needs lender approval. That non-dilutive capital matters because the two nearest readouts are binary: the tanruprubart BLA submission is expected in Q4 2026, and the ARCHER II Month 15 primary endpoint goes to an independent Data Monitoring Committee in Q4 2026, with sub-study results anticipated in Q1 2027 if the endpoint is met. A miss on ARCHER II or a delay in the BLA would hit the thesis hard; the credit facility buys time but does not remove that risk.
How filings like this one have moved
In the 30 days to Nov 9, 2026, 36.6% of the 2965 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ANNX was trading at $4.23 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $801.9M. The 52-week trading range was $2.54 to $7.18. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.